Lymphoma and Myeloma Program
The Lymphoma and Myeloma Program characterizes specific lymphoid malignancies at both the cellular and molecular levels, using state-of-the-art approaches such as murine models and broad-based transcriptional and genetic profiling. In addition to gaining basic insight into pathogenetic mechanisms and predisposing factors, these efforts help identify relevant rational treatment targets.
The Program has a long-standing interest in analysis and augmentation of host immune response to lymphomas and myelomas. Recently, investigators have developed an extensive outcomes database and have begun to analyze long-term toxicity and quality-of-life issues in lymphoma and myeloma patients.
The Lymphoma and Myeloma Program has four specific aims:
- Determine the etiologies of specific lymphoid malignancies with emphasis on viral causes
- Elucidate pathogenetic mechanisms underlying specific lymphoid neoplasms, focusing on:
- Informative chromosomal translocations and murine models
- Abnormalities of signal transduction pathways
- Interactions between the tumor and its microenvironment
- Develop novel therapeutic approaches to lymphoid malignancies, focusing on novel agents, risk-related therapy, high dose therapy with autologous or allogeneic stem cell support, tumor immunity including graft versus lymphoma effects, and tumor cell vaccines
- Develop a comprehensive mechanism to analyze sociodemographic, clinical, treatment, and outcomes data on lymphoma patients.
Status:
Active
Type:
Disease
Discipline:
Clinical Science
- A chromosome paint on a dividing cell from a mouse model of mature B-cell lymphoma, revealing translocations that will be characterized as part of the SCOR grant. [from Frederick Alt, PhD (CHB)]
